Telix Pharmaceuticals is trading 4.41% down at $11.18, based on live price context for August 26, 2026; no clearly dated company announcement was identified as directly explaining the decline.
- Bell Potter’s downgrade to Hold is a recent potential overhang but predates August 26.
- The company’s newly disclosed at-the-market equity facility also predates August 26 and does not establish today’s causation.